Pregnancy associated osteoporosis

Czech version

Authors: Ságová Ivana ^1,2; Mokáň Marián ²; Vaňuga Anton ^1,3; Tonhajzerová Rid ⁴; Rončáková Marianna ¹; Vaňuga Peter ¹
Authors‘ workplace: Endokrinologické oddelenie NEDÚ n. o., Ľubochňa ¹; I. Interná klinika JLF UK a UN Martin ²; Alpha Medical, s. r. o. ³; Ústav fyziológie JLF UK v Martine ⁴
Published in: Clinical Osteology 2023; 28(1-2): 11-18
Category:

Overview

Pregnancy associated osteoporosis is a very rare disease characterized by the occurrence of fractures during pregnancy or the puerperium. Despite its relative rarity, it is a dangerous condition that is clinically manifested by back pain, loss of height and it can lead to permanent disability. The exact etiology and pathogenesis of osteoporosis during pregnancy are still uncertain. There are currently no guidelines for the diagnosis and treatment of this type of osteoporosis. In our review article, we present current knowledge regarding bone metabolism during pregnancy, clinical manifestation, risk factors, location of fractures, possibilities of diagnosis and treatment of pregnancy-associated osteoporosis based on current data.

Keywords:

therapy – fractures – pregnancy – osteoporosis

Sources

1. Kyvernitakis I, Reuter TC, Hellmeyer L et al. Subsequent fracture risk of women with pregnancy and lactation-associated osteoporosis after a median of 6 years of follow-up. Osteoporos Int 2018; 29(1): 135–42. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–017–4239–1>.

2. Laroche M, Talibart M, Cormier C et al. Pregnancy-related fractures: a retrospective study of a French cohort of 52 patients and review of the literature. Osteoporos Int 2017; 28(11): 3135–3142. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–017–4165–2>.

3. Tuna F, Akleylek C, Ozdemir H et al. Risk factors, fractures, and management of pregnancy-associated osteoporosis: a retrospective study of 14 Turkish patients. Gynecol Endocrinol 2020; 36(3): 2 38–242. Dostupné z DOI: <http://dx.doi.org/10.1080/09513590.2019.1648417>.

4. Smith R, Stevenson JC, Winearls CG et al. Osteoporosis of pregnancy. Lancet 1985; 325(8439): 1178–1180. Dostupné z DOI: <http://dx.doi.org/10.1016/s0140–6736(85)92861–2>.

5. Hardcastle SA, Yahya F, Bhalla AK. Pregnancy-associated osteoporosis: a UK case series and literature review. Osteoporos Int 2019; 30(5): 939–948. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–019–04842-w>.

6. Hadji P, Boekhof J, Hahn M et al. Pregnancy-associated transient osteoporosis of the hip: results of a case control study. Arch Osteoporos 2017; 12(1): 11. Dostupné z DOI: <http://dx.doi.org/10.1007/s11657–017–0310-y>.

7. Paoletta M, Moretti A, Liguori S et al. Transient osteoporosis of the hip and subclinical hypothyroidism: an unusual dangerous duet? Case report and pathogenetic hypothesis. BMC Musculoskelet Disord 2020; 21(1): 543. Dostupné z DOI: <http://dx.doi.org/10.1186/s12891–020–03574-x>.

8. Grana E, Invernizzi M, Baricich A et al. A rare cause of Back pain during pregnancy and lactation: management and treatment. Pain M ed 2 016; 1 7(7): 1 382–1385. Dostupné z DOI: < http://dx.doi.org/10.1093/pm/pnv101>.

9. Terzi R, Terzi H, Ozer T et al. A rare cause of postpartum low Back pain: pregnancy- and lactation-associated osteoporosis. Biomed R es I nt 2 014; 2 014: 2 87832. Dostupné z DOI: < http://dx.doi.org/10.1155/2014/287832>.

10. Ekim AA, Eroglu P. Postpartum osteoporosis and thoracic vertebral fracture in a patient treated with heparin during pregnancy. J Clin Anal Med 2016; 7(Suppl 2): 154–157. Dostupné z DOI: < http://dx.doi.org/10.4328/JCAM.4465>.

11. Campos-Obando N, Oei L, Hoefsloot LH et al. Osteoporotic vertebral fractures during pregnancy: be aware of a potential underlying genetic cause. J Clin Endocrinol Metab 2014; 99(4): 1107–1111. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013–3238>.

12. Kovacs CS, Ralston SH. Presentation and management of osteoporosis presenting in association with pregnancy or lactation. Osteoporos Int 2015; 26(9): 2 223–2241. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–015–3149–3>.

13. Sanz-Salvador L, García-Pérez MÁ, Tarín JJ et al. Bone metabolic changes during pregnancy: a period of vulnerability to osteoporosis and fracture. Eur J Endocrinol 2015; 172(2): R53-R65. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-14–0424>.

14. Ritchie LD, Fung EB, Halloran BP et al.. A longitudinal study of calcium homeostasis during human pregnancy and lactation and after resumption o f m enses. A m J Clin Nutr 1 998; 6 7(4): 6 93–701. Dostupné z DOI: <http://dx.doi.org/10.1093/ajcn/67.4.693>.

15. Moller UK, Streym S, Mosekilde L et al. Changes in calcitropic hormones, bone markers and insulin-like growth factor I (IGF-I) during pregnancy and postpartum: a controlled cohort study. Osteoporosis International 2013; 24(4): 1307–1320. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–012–2062–2>.

16. Kirby BJ, Ma Y, Martin HM et al. Upregulation of calcitriol during pregnancy and skeletal recovery after lactation do not require parathyroid hormone. J Bone Miner Res 2013; 28(9): 1987–2000. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.1925>.

17. Lacroix MC, Guibourdenche J, Frendo JL et al. Human placental growth hormone – a review. Placenta 2002; 23(Suppl A): S87–94. Dostupné z DOI: <http://dx.doi.org/10.1053/plac.2002.0811>.

18. Mirlesse V, Frankenne F, Alsat E et al. Placental growth hormone levels in normal pregnancy and in pregnancies with intrauterine growth retardation. Pediatric Research 1993; 34(4): 439–442. Dostupné z DOI: <http://dx.doi.org/10.1203/00006450–199310000–00011>.

19. Chellakooty M, Vangsgaard K, Larsen T et al. A longitudinal study of intrauterine growth and the placental growth hormone (GH)–insulin-like growth factor I axis in maternal circulation: association between placental GH and fetal growth. J Clin Endocrinol Metab 2004; 89(1): 384–91. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2003–030282>.

20. Sigl V, Penninger JM. RANKL/RANK – from bone physiology to breast cancer. Cytokine Growth Factor Rev 2014; 25(2): 205–214. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cytogfr.2014.01.002>.

21. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. L ancet 2 011; 3 77(9773): 1276–1287.Dostupné z DOI: < http://dx.doi.org/10.1016/S0140–6736(10)62349–5>.

22. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008; 473(2): 139–146. Dostupné z DOI: <http://dx.doi.org/10.1016/j.abb.2008.03.018>.

23. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423(6937): 337–342. Dostupné z DOI: <http://dx.doi.org/10.1038/nature01658>.

24. Naylor KE, Rogers A, Fraser RB et al. Serum osteoprotegerin as a determinant of bone metabolism in longitudinal study of human pregnancy and lactation. J Clin Endocrinol Metab 2003; 88(11): 5361–5365. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2003–030486>.

25. Hong JS, Santolaya-Forgas J, Romero R et al. Maternal plasma osteoprotegerin concentration in normal pregnancy. Am J Obstet Gynecol 2005; 193(3 Pt 2): 1011–1015. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ajog.2005.06.051Z.

26. Lonergan M, Aponso D, Marvin KW et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm. J Clin Endocrinol Metab 2003; 88(8): 3835–3844. D ostupné z DOI: <http://dx.doi.org/10.1210/jc.2002–021905>.

27. Briana DD, Boutsikou M, Baka S et al. Circulating osteoprotegerin and sRANKL concentrations in the perinatal period at term. The impact of intrauterine growth restriction. Neonatology 2009; 96(2): 132–136. Dostupné z DOI: <http://dx.doi.org/10.1159/000211666>.

28. Dorota DK, Bogdan KG, Mieczyslaw G et al. The concentrations of markers of bone turnover in normal pregnancy and preeclampsia. Hypertens Pregnancy 2012; 31(1): 166–176. Dostupné z DOI: <http://dx.doi.org/10.3109/10641955.2010.484084>.

29. Findlay DM, Atkins GJ. Relationship between serum RANKL and RANKL in bone. Osteoporos Int 2011; 22(10): 2597–2602. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–011–1740–9>.

30. McClung MR, Grauer A, Boonen S et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014; 3 70(5): 4 12–420. D ostupné z DOI: < http://dx.doi.org/10.1056/NEJMoa1305224>.

31. Berndt T, Kumar R. Phosphatonins and the regulation of phosphate homeostasis. Annu Rev Physiol 2007; 69: 341–359. Dostupné z DOI: <http://dx.doi.org/10.1146/annurev.physiol.69.040705.141729>.

32. Godang K, Frøslie KF, Henriksen T et al. Umbilical cord levels of sclerostin, placental weight, and birth weight are predictors of total bone mineral content in neonates. Eur J Endocrinol 2013; 168(3): 371–378. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-12–0531>.

33. Frost M, Andersen T, Gossiel F et al. Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5. J Bone M iner R es 2 011; 2 6(8): 1721–1728. D ostupné z DOI: < http://dx.doi.org/10.1002/jbmr.376>.

34. Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol Metab 2012; 23(11): 576–581. Dostupné z DOI: <http://dx.doi.org/10.1016/j.tem.2012.03.008>.

35. Seriwatanachai D, Krishnamra N, van Leeuwen JP et al. Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J Cell Biochem 2009; 107(4): 677–685. Dostupné z DOI: <http://dx.doi.org/10.1002/jcb.22161>.

36. Seriwatanachai D, Thongchote K, Charoenphandhu N et al. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. B one 2 008; 42(3): 5 35–546. Dostupné z DOI: < http://dx.doi.org/10.1016/j.bone.2007.11.008>.

37. Hong N, Kim JE, Lee SJ et al. Changes in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy-and lactation-associated osteoporosis. Clin Endocrinol (Oxf) 2018; 8 8(5): 6 52–658. D ostupné z DOI: < http://dx.doi.org/10.1111/cen.13557>.

38. Della Martina M, Biasioli A, Vascotto L et al. Bone ultrasonometry measurements during pregnancy. Arch Gynecol Obstet 2010; 281(3): 401–407. Dostupné z DOI: <http://dx.doi.org/10.1007/s00404–009–1133-x>.

39. Lebel E, Mishukov Y, Babchenko L et al. Bone mineral density in gravida: Effect of pregnancies and breast-feeding in women of differing ages and parity. J Osteoporos 2014; 25: 355–356. Dostupné z DOI: <http://doi: 10.1155/2014/897182>.

40. Babbitt AM. Post-pregnancy osteoporosis (PPO) – a case study. J Clin Densitom 1998; 1(3): 269–273. Dostupné z DOI: <http://dx.doi.org/10.1385/jcd:1:3:269>.

41. Maliha G, Morgan J, Vrahas M. Transient osteoporosis of pregnancy. Injury 2012; 4 3(8): 1237–1241. Dostupné z DOI: <http://dx.doi.org/10.1016/j.injury.2012.03.009>.

42. Steib-Furno S, Luc M, Pham T et al. Pregnancy-related hip diseases: incidence and diagnoses. Joint Bone Spine 2007; 74(4): 373–378. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jbspin.2006.12.001>

43. Smith R, Athanasou NA, Ostlere SJ et al. Pregnancy-associated osteoporosis. QJM 1995; 88(12): 865–878.

44. Dunne F, Walters B, Marshall T et al. Pregnancy associated osteoporosis. Clin Endocrinol (Oxf) 1993; 39(4): 487–490. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2265.1993.tb02398.x>.

45. Carbone LD, Palmieri GM, Graves SC et al. Osteoporosis of pregnancy: long-term follow-up of patients and their offspring. Obstet Gynecol 1995; 8 6(4 Pt 2 ): 6 64–666. D ostupné z DOI: < http://dx.doi.org/10.1016/0029–7844(95)00226-h>.

46. Campos-Obando N, Oei L, Hoefsloot LH et al. Osteoporotic vertebral fractures during pregnancy: be aware of a potential underlying genetic cause. J Clin Endocrinol Metab 2014; 99(4): 1107–1111. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013–3238>

47. Osullivan SM, Grey AB, Singh R et al. Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporos Int 2006; 17(7): 1008–1012. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–006–0112–3>.

48. Hellmeyer L, Boekhoff J, Hadji P. Treatment with teriparatide in a patient with pregnancy-associated osteoporosis. Gynecol Endocrinol 2010; 26(10): 725–728. Dostupné z DOI: <http://dx.doi.org/10.3109/09513591003649831>.

49. Stumpf UC, Kurth AA, Windolf J et al. Pregnancy-associated osteoporosis: an underestimated and underdiagnosed severe disease. A review of two cases in short- and long-term follow-up. Adv Med Sci 2007; 52: 94–97.

50. Groen RS, Bae JY, Lim KJ. Fear of the unknown: ionizing radiation exposure during pregnancy. Am J Obstet Gynecol 2012; 206(6): 456–462. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ajog.2011.12.001>.

51. Bazzocchi A, Garzillo G, Fuzzi F et al. Localizer sequences of magnetic resonance imaging accurately identify osteoporotic vertebral fractures. Bone 2014; 61: 158–163. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2014.01.013>.

52. Vande Berg BC, Malghem JJ, Lecouvet FE et al. Idiopathic bone marrow edema lesions of the femoral head: predictive value of MR imaging findings. Radiology 1999; 212(2): 527–535. Dostupné z DOI: <http://dx.doi.org/10.1148/radiology.212.2.r99au03527>.

53. Sánchez A, Zanchetta MB, Danilowicz K. Two cases of pregnancyand lactation- associated osteoporosis successfully treated with denosumab. C lin C ases M iner B one M etab 2 016; 13(3): 2 44–246. Dostupné z DOI: <http://dx.doi.org/10.11138/ccmbm/2016.13.3.244>.

54. Patlas N, Golomb G, Yaffe P et al. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 1 999; 60(2): 68–73. Dostupné z DOI: <http://dx.doi.org/10.1002/(SICI)1096–9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H>.

55. Ornoy A, Wajnberg R, Diav-Citrin O. The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 2006; 22(4); 578–579. Dostupné z DOI: <http://dx.doi.org/10.1016/j.reprotox.2006.05.009>.

56. Levy S, Fayez I, Taguchi N et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone 2009; 44(3): 428–430. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2008.11.001

57. Djokanovic N, Klieger-Grossmann C et al. Does treatment with bisphosphonates endanger the human pregnancy? Obstet Gynaecol Can 2008; 30(12): 1146–1148. Dostupné z DOI: <http://dx.doi.org/10.1016/S1701–2163(16)34026–9>.

58. Rutgers-Verhage AR, deVries TW, Torringa MJ. No effects of bisphosphonates on the human fetus. Birth Defects Res A Clin Mol Teratol 2003; 67(3): 203–204. Dostupné z DOI: <http://dx.doi.org/10.1002/bdra.10016>.

59. Polat SB, Evranos B, Aydin C et al. Effective treatment of severe pregnancy and lactation-related osteoporosis with teriparatide: case report and review of the literature. Gynecol Endocrinol 2015; 31(7): 522–525. Dostupné z DOI: <http://dx.doi.org/10.3109/09513590.2015.1014787>.

60. FORSTEO (Teriparatide injection). Product information. Eli Lilly and Co: 2002. Dostupné z WWW: <https://ec.europa.eu/health/documents/community-register/2005/200504279560/anx_9560_it.pdf>.

61. Bussiere JL, Pyrah I, Boyce R et al. Reproductive toxicity of denosumab in cynomolgus monkeys. Reprod Toxicol 2013; 42: 27–40. Dostupné z DOI: <http://dx.doi.org/10.1016/j.reprotox.2013.07.018>.

62. Akiyama T, Shinzawa M, Akiyama N. RANKL-RANK interaction in immune regulatory systems. World J Orthop 2012; 3(9): 142–150. Dostupné z DOI: <http://dx.doi.org/10.5312/wjo.v3.i9.142>.

63. PROLIA (Denosumab). Product information. AMGEN inc.; 2010. Dostupné z WWW: <https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Prolia/prolia_pi.pdf>.

64. Isobe F, Nakamura Y, Kamimura M et al. Effects of Denosumab Treatment during Early Pregnancy – A Case Report. J Nutr Disorders Ther 2 016; 6 :2. D ostupné z DOI: < http://dxdoi.org/10.4172/2161–0509.1000189>.

65. Sánchez A, Zanchetta MB, Danilowicz K. Two cases of pregnancy – and lactation- associated osteoporosis successfully treated with denosumab. Clin Cases Miner Bone Metab 2016; 13(3): 244–246. Dostupné z DOI: <http://dx.doi.org/10.11138/ccmbm/2016.13.3.244>.

66. Ijuin A, Yoshikata H, Asano R et al. Teriparatide and denosumab treatment for pregnancy and lactation-associated osteoporosis with multiple vertebral fractures: A case study. Taiwan J Obstet Gynecol 2017; 56(6): 863–866. Dostupné z DOI: <http://dx.doi.org/10.1016/j.tjog.2017.10.028>.

67. Kaneuchi Y, Iwabuchi M, Hakozaki M et al. Pregnancy and Lactation-Associated Osteoporosis Successfully Treated with Romosozumab: A Case Report. Medicina (Kaunas) 2023; 59(1): 19. Dostupné z DOI: <http://dx.doi.org/10.3390/medicina59010019>.

68. EVENITY (romosozumab). Product information. Dostupné z WWW: <https://www.ema.europa.eu/en/documents/product-information/evenity-epar-product-information_en.pdf>.

69. Guideline: Calcium Supplementation in Pregnant Women. World Health Organization: Geneva 2013. ISBN 978–92–4-150537 6.

70. Guideline: Vitamin D Supplementation in Pregnant Women. World Health Organization: Geneva 2012. ISBN 978–92–4-150493.

Labels

Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology Osteology

Jak a čím žije česká klinická osteologie v dnešní době

Fracture Liaison Service: pilot project in FH Královské Vinohrady

The role of senescence in the development of osteoporosis and osteoarthritis

Reflection on the causes of senile osteoporosis

Exostosis of proximal femur – benign tumor, “malign” location: a case report

Latest research and news in osteology

Sterile Inflammation after Radiofrequency Ablation of Osteoid Osteoma: A Case Report

Article was published in

Clinical Osteology

2023 Issue 1-2